...Agency action unlikely to affect Covis’ pending $498M takeout of AMAG By Steve Usdin, Washington Editor...
...proposal probably will not affect last week’s proposed acquisition of AMAG by Luxembourg-based specialty pharma Covis...

...the gene therapy to treat Duchenne muscular dystrophy.Covis to acquire AMAG, marketer of Makena Luxembourg-based specialty pharma Covis...
...million shares at $15, the midpoint of its proposed $14-16 range. BC Staff Veklury, remdesivir (GS-5734) SGT-001 Mesoblast Ltd. Gilead Sciences Inc. Solid Biosciences Covis Beckman...

...ex-U.S. rights to Alvesco, Omnaris and Zetonna from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $350 million. Covis...
...and Zetonna are nasal sprays indicated to treat rhinitis. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Covis Pharma S.a.r.l....
...Business: Inflammation Shannon Lehnbeuter Alvesco, ciclesonide (inhaled) Omnaris, ciclesonide nasal spray Zetonna (Brand), ciclesonid (Generic), Zetonna nasal aerosol (Informal) AstraZeneca plc Covis Pharma S.a.r.l....

...testosterone blocker is marketed to treat metastatic prostate cancer. Under a 2013 deal, Sanofi granted Covis Pharma S.a.r.l....
...Switzerland) U.S. rights to Nilandron. In 2015, Concordia Healthcare Corp. (TSX:CXR; NASDAQ:CXRX, Oakville, Ontario) acquired Covis’...

...Concordia completed its acquisition of Covis’ commercial assets, specifically its 18 branded and generic products, for...
...its 18 branded and generic products, for $1.2 billion in cash (see BioCentury, March 16). Covis Pharma S.a.r.l....

...TD Securities Note: Concordia sold subscription receipts. Upon closing of a deal between Concordia and Covis Pharma S.a.r.l....
...terminated, receipt holders will be refunded the subscription price plus interest earned. Concordia is purchasing Covis’...

...Covis’ commercial assets, specifically its 18 branded and generic products, for $1.2 billion in cash. Covis...
...formulation of hydroxychloroquine, which is marketed to treat malaria. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) granted Covis...
...rights to commercialize Nilandron and Plaquenil in 2013. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) granted Covis...

...symptom onset. The only marketed treatment for the disease is Rilutek riluzole from Sanofi and Covis Pharma S.a.r.l....
...centralized location Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Cedars-Sinai Medical Center , Los Angeles, Calif. Covis Pharma S.a.r.l....

...of $240. The company already markets 0.25 and 0.125 mg strengths. In 2011, GlaxoSmithKline granted Covis...
...U.S. and Puerto Rican rights to commercialize the cardiac glycoside (see BioCentury, Jan. 2, 2012). Covis Pharma S.a.r.l....